Filing Details
- Accession Number:
- 0001209191-23-011387
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-21 19:29:20
- Reporting Period:
- 2023-02-17
- Accepted Time:
- 2023-02-21 19:29:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1706431 | Vir Biotechnology Inc. | VIR | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1202102 | A George Scangos | C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-12-21 | 49,984 | $0.00 | 827,151 | No | 4 | J | Indirect | See footnote |
Common Stock | Acquisiton | 2022-12-21 | 49,984 | $0.00 | 111,644 | No | 4 | J | Indirect | See footnote |
Common Stock | Disposition | 2022-12-21 | 49,984 | $0.00 | 827,151 | No | 4 | J | Indirect | See footnote |
Common Stock | Acquisiton | 2022-12-21 | 49,984 | $0.00 | 111,644 | No | 4 | J | Indirect | See footnote |
Common Stock | Disposition | 2023-01-18 | 64,930 | $0.00 | 3,533,629 | No | 4 | J | Indirect | See footnote |
Common Stock | Acquisiton | 2023-01-18 | 64,930 | $0.00 | 179,930 | No | 4 | J | Indirect | See footnote |
Common Stock | Disposition | 2023-02-17 | 9,894 | $25.29 | 214,095 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-21 | 11,382 | $28.02 | 202,713 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-21 | 6,474 | $28.80 | 196,239 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | J | Indirect | See footnote |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transfer without consideration for tax planning purposes.
- The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
- The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
- The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
- The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
- The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
- The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
- Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
- Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $29.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.